These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 26039159)

  • 1. Amyloids or prions? That is the question.
    Sabate R; Rousseau F; Schymkowitz J; Batlle C; Ventura S
    Prion; 2015; 9(3):200-6. PubMed ID: 26039159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What makes a protein sequence a prion?
    Sabate R; Rousseau F; Schymkowitz J; Ventura S
    PLoS Comput Biol; 2015 Jan; 11(1):e1004013. PubMed ID: 25569335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid cores in prion domains: Key regulators for prion conformational conversion.
    Fernández MR; Batlle C; Gil-García M; Ventura S
    Prion; 2017 Jan; 11(1):31-39. PubMed ID: 28281928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlling the prion propensity of glutamine/asparagine-rich proteins.
    Paul KR; Ross ED
    Prion; 2015; 9(5):347-54. PubMed ID: 26555096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide sequences converting polyglutamine into a prion in yeast.
    Odani W; Urata K; Okuda M; Okuma S; Koyama H; Pack CG; Fujiwara K; Nojima T; Kinjo M; Kawai-Noma S; Taguchi H
    FEBS J; 2015 Feb; 282(3):477-90. PubMed ID: 25406629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PrionW: a server to identify proteins containing glutamine/asparagine rich prion-like domains and their amyloid cores.
    Zambrano R; Conchillo-Sole O; Iglesias V; Illa R; Rousseau F; Schymkowitz J; Sabate R; Daura X; Ventura S
    Nucleic Acids Res; 2015 Jul; 43(W1):W331-7. PubMed ID: 25977297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of yeast to studying amyloid and prion diseases.
    Chernoff YO; Grizel AV; Rubel AA; Zelinsky AA; Chandramowlishwaran P; Chernova TA
    Adv Genet; 2020; 105():293-380. PubMed ID: 32560789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When amyloids become prions.
    Sabate R
    Prion; 2014; 8(3):233-9. PubMed ID: 24831240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opposing effects of glutamine and asparagine govern prion formation by intrinsically disordered proteins.
    Halfmann R; Alberti S; Krishnan R; Lyle N; O'Donnell CW; King OD; Berger B; Pappu RV; Lindquist S
    Mol Cell; 2011 Jul; 43(1):72-84. PubMed ID: 21726811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of glutamine/asparagine content on aggregation and heterologous prion induction by yeast prion-like domains.
    Shattuck JE; Waechter AC; Ross ED
    Prion; 2017 Jul; 11(4):249-264. PubMed ID: 28665753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Q/N-rich, polyQ, and non-polyQ amyloids on the de novo formation of the [PSI+] prion in yeast and aggregation of Sup35 in vitro.
    Derkatch IL; Uptain SM; Outeiro TF; Krishnan R; Lindquist SL; Liebman SW
    Proc Natl Acad Sci U S A; 2004 Aug; 101(35):12934-9. PubMed ID: 15326312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prion, prionoids and infectious amyloid.
    Liberski PP
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S80-4. PubMed ID: 24262195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A census of glutamine/asparagine-rich regions: implications for their conserved function and the prediction of novel prions.
    Michelitsch MD; Weissman JS
    Proc Natl Acad Sci U S A; 2000 Oct; 97(22):11910-5. PubMed ID: 11050225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fitting yeast and mammalian prion aggregation kinetic data with the Finke-Watzky two-step model of nucleation and autocatalytic growth.
    Watzky MA; Morris AM; Ross ED; Finke RG
    Biochemistry; 2008 Oct; 47(40):10790-800. PubMed ID: 18785757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Key Points Concerning Amyloid Infectivity and Prion-Like Neuronal Invasion.
    Espargaró A; Busquets MA; Estelrich J; Sabate R
    Front Mol Neurosci; 2016; 9():29. PubMed ID: 27147962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of amino acid composition on yeast prion formation and prion domain interactions.
    Ross ED; Toombs JA
    Prion; 2010; 4(2):60-5. PubMed ID: 20495349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Can prion-like propagation occur in neurodegenerative diseases?: in view of transmissible systemic amyloidosis].
    Yoshida K; Higuchi K; Ikeda S
    Brain Nerve; 2012 Jun; 64(6):665-74. PubMed ID: 22647474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic prions and other human neurodegenerative proteinopathies.
    Le NT; Narkiewicz J; Aulić S; Salzano G; Tran HT; Scaini D; Moda F; Giachin G; Legname G
    Virus Res; 2015 Sep; 207():25-37. PubMed ID: 25449570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The allure and pitfalls of the prion-like aggregation in neurodegeneration.
    Ezzat K; Espay AJ
    Handb Clin Neurol; 2023; 193():17-22. PubMed ID: 36803809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloids of shuffled prion domains that form prions have a parallel in-register beta-sheet structure.
    Shewmaker F; Ross ED; Tycko R; Wickner RB
    Biochemistry; 2008 Apr; 47(13):4000-7. PubMed ID: 18324784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.